DKM 428
Alternative Names: DKM-428Latest Information Update: 22 Jul 2025
At a glance
- Originator Dongkook Pharmaceutical
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Clinical Phase Unknown Skin disorders
Most Recent Events
- 15 Jul 2025 Clinical trials in Skin disorders in South Korea (unspecified route), before July 2025 (Dongkook pharmaceuticals pipeline, July 2025)